Pharma Pulse 9/20/24: The Benefit to Adapting Operating Models, 50% of US Women Skip or Delay Medical Care & more

DPHARM 2024: The Benefit to Adapting Operating Models

DPHARM 2024 carried on with a leadership panel that revolved around "How Pharma is Shifting Operating Models for More Efficient Clinical Trials.” Moderated by Bari Kowal, SVP, development operations, portfolio management & biostatistics data management at Regeneron Pharmaceuticals Inc., she was joined by Deirdre BeVard, SVP, R&D strategic operation at CSL Behring; Candice Fitzgerald, MMedSc, head of CD&O regions at Boehringer Ingelheim; Angela DeLuca, MBA, PMP associate VP, head of global study operations at Amgen; and Staci Hargraves, MBA, VP, innovative health, engagement & advocacy at Johnson & Johnson Innovative Medicine, who expressed that the duty that operating models have—which is to tackle the complexities of science, technology, and regulatory requirements—couldn’t be any more essential.

Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.

California Passes Election ‘Deepfake’ Laws, Forcing Social Media Companies to Take Action

The state joins dozens of others in regulating the A.I. fakery in ways that could impact this year’s presidential race.

Deloitte Analysis: 50% of US Women Skip or Delay Medical Care due to Cost, Access, or Negative Experiences

Findings show women avoid care at much higher rate than men, potentially impacting their long-term health and wealth.

Parexel on LinkedIn

In our recent poll, we asked about the key drivers behind the growing adoption of the Functional Service Provider (FSP) model. The results were clear: nearly 40% of respondents believe the need for more agile service models is paramount, while 32% pointed to the increasing complexity and volume of clinical studies as a significant factor. Both highlight the growing demand for scalable resources.

These findings align with insights from Jenny Denney, MBA, PMP, Global Head, Parexel FSP, who recently discussed the rise of FSP models in Pharmaceutical Executive. While FSPs offer numerous benefits, life sciences companies must also understand the full capabilities associated with this approach to maximize its potential.

Click through to learn more about her recommendations and explore the full interview here: https://lnkd.in/gS_Gn6uZ

#FSP #clinicaltrials #agility #PharmaExec

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs